Telix Pharmaceuticals (ASX:TLX) completed its acquisition of US radiopharmacy network RLS for an upfront cash payment of $230 million and a deferred payment of $20 million, according to a Tuesday filing with the Australian bourse.
RLS will continue to operate as a standalone business within Telix Manufacturing Solutions, per the filing. The deal is part of the biopharmaceutical company's strategy to create an integrated radiopharmaceutical ecosystem.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.